MADRIGAL PHARMACEUTICALS, INC. cotiza a 452.12 USD y tiene una capitalización bursátil de $10.4B. En los últimos 12 meses ha facturado $1.3B con un margen de flujo de caja libre del -19.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is he…
| Periodo | 2026-11 | 2026-07 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-1.99 | $-1.38 | $-2.57 |
| Estimado | $-1.09 | $-2.23 | $-4.14 | $-0.88 |
| Sorpresa | — | +10.8% | +66.7% | -192.0% |
| Métrica | MDGL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -31.3% | -38.6% | +7.3% |
| Net Margin | -30.1% | -33.6% | +3.5% |
| FCF Margin | -19.8% | -13.9% | -6.0% |
| ROE | -47.8% | -40.4% | -7.4% |
| ROA | -22.9% | -32.0% | +9.1% |
| Current Ratio | 4.01 | 2.84 | +1.17 |
| Debt / Equity | 0.56 | 0.28 | +0.28 |